

Special Issue

Recent Advances in the Development of Innovative Anticancer Agents and Antitumor Strategies

Message from the Guest Editors

This Special Issue is intended to provide insights into the recent developments in cancer research, highlighting the potential impact in the field. We welcome original research papers, insightful review articles, and impactful short communications dealing with the development of novel strategies for cancer treatment. In particular, submissions that focus on a wide range of anticancer approaches, dealing with medicinal chemistry, pharmaceuticals, and supramolecular strategies, are welcome. These include, but are not limited to, the design, synthesis, and biological evaluation of active small molecules, polypharmacological agents, hybrid compounds, conjugates, prodrugs, and fluorescent probes, as well as the development of controlled drug delivery systems and supramolecular nanoassemblies, including organic–inorganic hybrid nanomaterials for drug delivery and cancer theranostics. We look forward to hearing from you.

Guest Editors

Dr. Sebastiano Intagliata

Dr. Elisa Magli

Dr. Mariachiara Trapani

Deadline for manuscript submissions

28 February 2027



Molecules

an Open Access Journal
by MDPI

Impact Factor 5.1
CiteScore 10.3
Indexed in PubMed



mdpi.com/si/262951

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 5.1
CiteScore 10.3
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).